Hepatitis C, Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

table  3.   Causes of Death


Causes of Death Total Sclerotherapy TIPS

Exsanguination N° (% deaths) 6 (35.3) 3 (37.5) 3 (33.3)
Bleeding-related N° (% deaths) 2 (11.8) 1 (12.5) 1 (11.1)
Liver failure N° (% deaths) 7 (41.1) 4 (50.0) 3 (33.3)
Other* N° (% deaths) 2 (11.8) 0 2 (22.2)
Total N° (% deaths) 17 (100.0) 8 (100.0) 9 (100.0)

* Hepatocellular carcinoma, intestinal occlusion.


Return To Article

Table Of Contents